At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 602 enrolled
Drug / intervention
GW642444 6.25 +5 moredrug
Likely dose
GW642444 3mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study B2C111045, A Dose-Finding Study of GW642444 Versus Placebo in Patients With COPD
In Brief
A Phase 2 clinical trial evaluating GW642444 6.25, GW642444 3mcg, and 4 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 602 participants across 99 sites in 14 countries.
Detailed Summary
This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesArgentina, Canada, Chile, Denmark, Estonia, Germany, Mexico, Peru, Philippines, Poland, Russia, Slovakia, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedFeb 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedFeb 4, 2008
Enrollment StartFeb 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.4 years ago
Interventions
GW642444 6.25drug
GW642444 6.25
GW642444 3mcgdrug
once daily
GW642444 12.5mcgdrug
GW642444 12.5mcg
GW642444 25mcgdrug
GW642444 25mcg
GW642444 50mcgdrug
GW642444 50mcg
placeboother
placebo